NRIX - Nurix Therapeutics, Inc.
IEX Last Trade
19.74
0.020 0.101%
Share volume: 18,776
Last Updated: Thu 26 Dec 2024 08:30:21 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$19.72
0.02
0.10%
Fundamental analysis
21%
Profitability
18%
Dept financing
9%
Liquidity
68%
Performance
16%
Performance
5 Days
-2.05%
1 Month
-10.19%
3 Months
-15.68%
6 Months
-4.35%
1 Year
102.17%
2 Year
88.54%
Key data
Stock price
$19.74
DAY RANGE
$19.02 - $19.74
52 WEEK RANGE
$8.17 - $29.56
52 WEEK CHANGE
$82.73
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/10/2024
Company detail
CEO: Arthur T. Sands
Region: US
Website: nurixtx.com
Employees: 300
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: nurixtx.com
Employees: 300
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies. NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy, is in Phase 1 clinical trials for gynecologic cancers, including ovarian, endometrial, and cervical cancer.
Recent news